Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -53,489 | -46,484 | -11,233 | -33,818 | -24,201 |
| Depreciation Amortization | 14,316 | 14,217 | 108 | 268 | 159 |
| Income taxes - deferred | -3,124 | -2,591 | -1,382 | -2,315 | N/A |
| Accounts receivable | -115 | 43 | -474 | 28 | -189 |
| Accounts payable and accrued liabilities | 1,793 | 1,656 | 1,739 | -223 | -788 |
| Other Working Capital | 4,099 | 2,475 | 1,701 | 1,201 | 108 |
| Other Operating Activity | 16,120 | 14,860 | 220 | 10,271 | 9,183 |
| Operating Cash Flow | $-20,400 | $-15,824 | $-9,321 | $-24,588 | $-15,729 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | -7 | N/A | -137 | -109 |
| Net Acquisitions | N/A | N/A | N/A | -1,849 | -1,849 |
| Other Investing Activity | 0 | 0 | 0 | -4,382 | 0 |
| Investing Cash Flow | $-7 | $-7 | $N/A | $-6,368 | $-1,957 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 13,331 | 9,492 | N/A | 42,333 | 9,802 |
| Other Financing Activity | -2,614 | -1,961 | 0 | -4,525 | 28,006 |
| Financing Cash Flow | $10,717 | $7,531 | $N/A | $37,808 | $37,808 |
| Beginning Cash Position | 10,163 | 10,163 | 10,163 | 3,311 | 3,311 |
| End Cash Position | 473 | 1,863 | 842 | 10,163 | 23,433 |
| Net Cash Flow | $-9,690 | $-8,300 | $-9,321 | $6,852 | $20,123 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,400 | -15,824 | -9,321 | -24,588 | -15,729 |
| Capital Expenditure | -7 | -7 | N/A | -137 | -109 |
| Free Cash Flow | -20,407 | -15,831 | -9,321 | -24,725 | -15,837 |